BTIG Research Drops Coverage on Zoetis (NYSE:ZTS)

Research analysts at BTIG Research dropped coverage on shares of Zoetis (NYSE:ZTS) in a research note issued on Friday, Benzinga reports. The brokerage had previously set a “buy” rating on the stock.

ZTS has been the subject of several other research reports. William Blair cut Zoetis from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 6th. Piper Sandler reduced their price objective on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, August 10th. BNP Paribas Exane decreased their price objective on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. Morgan Stanley reduced their price target on shares of Zoetis from $85.00 to $82.00 and set an “overweight” rating on the stock in a research report on Thursday. Finally, Jefferies Financial Group downgraded shares of Zoetis from a “buy” rating to a “hold” rating and reduced their target price for the stock from $103.00 to $83.00 in a report on Tuesday, October 20th. Six research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $93.79.

Zoetis Stock Performance

Shares of ZTS stock traded up $0.87 on Friday, reaching $79.67. The stock had a trading volume of 4,115,503 shares, compared to its average volume of 5,429,776. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis has a 1 year low of $68.77 and a 1 year high of $144.83. The stock has a market cap of $32.92 billion, a P/E ratio of 13.13, a price-to-earnings-growth ratio of 1.15 and a beta of 0.74. The company has a 50 day simple moving average of $74.95 and a 200 day simple moving average of $93.86.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The company had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the prior year, the business earned $1.76 earnings per share. Zoetis’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities research analysts expect that Zoetis will post 6.15 EPS for the current year.

Institutional Trading of Zoetis

Hedge funds have recently bought and sold shares of the stock. Physician Wealth Advisors Inc. grew its stake in Zoetis by 17.4% during the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after buying an additional 91 shares during the period. Lipe & Dalton raised its stake in shares of Zoetis by 2.2% in the 1st quarter. Lipe & Dalton now owns 4,698 shares of the company’s stock valued at $555,000 after acquiring an additional 102 shares during the period. Root Financial Partners LLC raised its stake in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares during the period. Valmark Advisers Inc. lifted its holdings in shares of Zoetis by 7.7% during the 1st quarter. Valmark Advisers Inc. now owns 1,747 shares of the company’s stock valued at $207,000 after acquiring an additional 125 shares in the last quarter. Finally, Balefire LLC lifted its holdings in shares of Zoetis by 6.7% during the 1st quarter. Balefire LLC now owns 1,996 shares of the company’s stock valued at $236,000 after acquiring an additional 125 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.